Therapeutic and Radiosensitizing Effects of Armillaridin on Human Esophageal Cancer Cells

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Cell lines</td><td align="center">IC<sub>50</sub></td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Squamous cell carcinoma</td><td align="center"> </td></tr><tr><td align="left"> CE81T/VGH</td><td align="center">6.9 <i>μ</i>M </td></tr><tr><td align="left"> TE-2</td><td align="center">3.4 <i>μ</i>M </td></tr><tr><td align="left">Adenocarcinoma</td><td align="center"> </td></tr><tr><td align="left"> BE-3</td><td align="center">5.4 <i>μ</i>M </td></tr><tr><td align="left"> SKGT-4</td><td align="center">5.5 <i>μ</i>M </td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

The half maximal inhibitory concentration (IC<sub>50</sub>) of Armillaridin on various human esophageal cancer cell lines.

Evidence-Based Complementary and Alternative Medicine

tab1

Table 1

Table 1: Therapeutic and Radiosensitizing Effects of Armillaridin on Human Esophageal Cancer Cells 